NCT03145948 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

August 16, 2017

Study Completion Date

August 16, 2017

Conditions

Psoriasis

Interventions

DRUG

ABBV-553

It is administered orally.

DRUG

Placebo

It is administered orally.

Trial Locations (4)

Progressive Medical Research /ID# 163868, Port Orange

Abbvie Clinical Pharmacology Research Unit /ID# 163866, Grayslake

Providence Clinical Research /ID# 163867, Toluca

Anaheim Clinical Trials LLC /ID# 164101, Anaheim